Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, is expanding its BioProcess Innovation Center in Research Triangle Park (RTP).
The project, which will feature an additional 89,000 square feet of laboratory space equipped with state-of-the-art analytical instrumentation, high throughput bioprocessing equipment and automation technologies, is expected to double the CDMO’s capacity to support process characterization programs and complements the enhanced capabilities at its UK facility. This expansion will also allow Fujifilm Diosynth Biotechnologies to further support its partners in guiding clinical process development that can create more robust commercial processes.
The expanded space is expected to be operational by mid-2024, which is also when approximately 145 new jobs are anticipated to open up, many of those positions being for researchers and scientists.
“ … We are delighted to be adding this additional capacity to support our growing pipeline of customers,” notes Christine Vannais, chief operating officer, Fujifilm Diosynth Biotechnologies, RTP, North Carolina. “The cutting-edge laboratory equipment and automation tools, combined with the deep technical expertise of our scientific community, will allow us to better serve our partners to rapidly generate and assess data to understand complex molecules, along with the processes used in their manufacture.”